Sector News

Sanofi turns to AI to cut Chinese recruitment churn

February 13, 2020
Life sciences

As the hunt for skilled employees in China intensifies, pharmaceutical group Sanofi is using artificial intelligence to identify the most promising and loyal applicants.

“We are facing a very fierce talent war, not just from multinationals but from a lot of Chinese companies that want to expand,” says Iris Zhou, head of talent acquisition for Asia Pacific.

Sanofi has been using an algorithm for the past two years to assess interns on their potential cultural fit with the organisation. Only then are the shortlisted candidates interviewed by HR staff.

> Read the full article on the Financial Times website

By Andrew Jack

Source: Financial Times

1 response to “Sanofi turns to AI to cut Chinese recruitment churn

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend